drugset / Trial / NCT01364727
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
NaSingle-groupOpen-labelOther
Summary
A research study of the drug amrubicin in patients with cancer of the thymus (thymoma or thymic carcinoma). We hope to learn whether this drug is an effective and safe treatment for thymic cancers.
Timeline
- Start
- 2011-06
- Primary completion
- 2014-07
- Completion
- 2018-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amrubicin | Small molecule | 35 mg/m2 | Intravenous |